DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its first product, GlucoSitter, an artificial pancreas technology which was licensed to Medtronic Diabetes. Ever since, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in the diabetes management space. DreaMed became the first and only company in the world to receive FDA clearance for DreaMed Advisor Pro, a decision support system in Type I diabetes patients using data from CGM/SMBG and insulin pumps. The company is continuing to develop the DreaMed Advisor portfolio which will aid all people living with diabetes no matter the insulin therapy or diabetes type and their healthcare professionals to provide personalized insulin therapy.

Medical Devices

DreaMed Diabetes

Eran Atlas

Erez Nahshon

Doron Hoffman

Inbar Sagi

Yael Shtrit

Ido Mueller

Ryan Hovey

Noy Ben Moyal

Thomas Danne

Revital Nimri

Tadej Battelino

The leadership team at DreaMed Diabetes has a history of experience in regulatory affairs, project management, marketing, and sales. They have also worked for companies such as UnitedHealth Group and Surescripts. They hold degrees from Tel Aviv University and Tianjin Foreign Studies University.

Leadership Team

Founding Team

CEO and Executive Team

Leadership Team

About

Team members

Other teams at DreaMed Diabetes

Founding Team

CEO and Executive Team